These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1057 related articles for article (PubMed ID: 29358661)

  • 21. Metabolic characterization of imatinib-resistant BCR-ABL T315I chronic myeloid leukemia cells indicates down-regulation of glycolytic pathway and low ROS production.
    Ko BW; Han J; Heo JY; Jang Y; Kim SJ; Kim J; Lee MJ; Ryu MJ; Song IC; Jo YS; Kweon GR
    Leuk Lymphoma; 2016 Sep; 57(9):2180-8. PubMed ID: 26854822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition.
    Mitchell R; Hopcroft LEM; Baquero P; Allan EK; Hewit K; James D; Hamilton G; Mukhopadhyay A; O'Prey J; Hair A; Melo JV; Chan E; Ryan KM; Maguer-Satta V; Druker BJ; Clark RE; Mitra S; Herzyk P; Nicolini FE; Salomoni P; Shanks E; Calabretta B; Holyoake TL; Helgason GV
    J Natl Cancer Inst; 2018 May; 110(5):467-478. PubMed ID: 29165716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1
    Schneeweiss-Gleixner M; Byrgazov K; Stefanzl G; Berger D; Eisenwort G; Lucini CB; Herndlhofer S; Preuner S; Obrova K; Pusic P; Witzeneder N; Greiner G; Hoermann G; Sperr WR; Lion T; Deininger M; Valent P; Gleixner KV
    EBioMedicine; 2019 Dec; 50():111-121. PubMed ID: 31761618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML).
    Wu J; Wang A; Li X; Chen C; Qi Z; Hu C; Wang W; Wu H; Huang T; Zhao M; Wang W; Hu Z; Liu Q; Wang B; Wang L; Li L; Ge J; Ren T; Xia R; Liu J; Liu Q
    Cancer Biol Ther; 2019; 20(6):877-885. PubMed ID: 30894066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.
    Bandyopadhyay S; Li J; Traer E; Tyner JW; Zhou A; Oh ST; Cheng JX
    PLoS One; 2017; 12(7):e0179558. PubMed ID: 28719608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells.
    Matsuda Y; Yamauchi T; Hosono N; Uzui K; Negoro E; Morinaga K; Nishi R; Yoshida A; Kimura S; Maekawa T; Ueda T
    Cancer Sci; 2016 Jul; 107(7):1029-38. PubMed ID: 27166836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation.
    Wang LX; Wang JD; Chen JJ; Long B; Liu LL; Tu XX; Luo Y; Hu Y; Lin DJ; Lu G; Long ZJ; Liu Q
    Sci Rep; 2016 Nov; 6():35533. PubMed ID: 27824120
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor α and bcr-abl oncogene addiction in malignant hematologic cells.
    Wu Y; Chen C; Sun X; Shi X; Jin B; Ding K; Yeung SC; Pan J
    Clin Cancer Res; 2012 Apr; 18(7):1966-78. PubMed ID: 22447844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PBA2, a novel inhibitor of the β-catenin/CBP pathway, eradicates chronic myeloid leukemia including BCR-ABL T315I mutation.
    Yang K; Fu K; Zhang H; Wang X; To KKW; Yang C; Wang F; Chen ZS; Fu L
    Mol Cancer; 2024 Sep; 23(1):209. PubMed ID: 39342174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
    Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
    Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
    [TBL] [Abstract][Full Text] [Related]  

  • 31. All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.
    Cassuto O; Dufies M; Jacquel A; Robert G; Ginet C; Dubois A; Hamouda A; Puissant A; Luciano F; Karsenti JM; Legros L; Cassuto JP; Lenain P; Auberger P
    Oncotarget; 2012 Dec; 3(12):1557-65. PubMed ID: 23238683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.
    Ben-Batalla I; Erdmann R; Jørgensen H; Mitchell R; Ernst T; von Amsberg G; Schafhausen P; Velthaus JL; Rankin S; Clark RE; Koschmieder S; Schultze A; Mitra S; Vandenberghe P; Brümmendorf TH; Carmeliet P; Hochhaus A; Pantel K; Bokemeyer C; Helgason GV; Holyoake TL; Loges S
    Clin Cancer Res; 2017 May; 23(9):2289-2300. PubMed ID: 27856601
    [No Abstract]   [Full Text] [Related]  

  • 33. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
    Lee J; Shen P; Zhang G; Wu X; Zhang X
    Biomed Pharmacother; 2013 Mar; 67(2):157-63. PubMed ID: 23201011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway.
    Huang R; Liu H; Chen Y; He Y; Kang Q; Tu S; He Y; Zhou X; Wang L; Yang J; Wu A; Li Y
    Oncol Rep; 2018 Jan; 39(1):119-128. PubMed ID: 29192326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Lu Z; Jin Y; Qiu L; Lai Y; Pan J
    Cancer Lett; 2010 Apr; 290(2):182-91. PubMed ID: 19819619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: Antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl.
    Xu F; Shi X; Li S; Cui J; Lu Z; Jin Y; Lin Y; Pang J; Pan J
    Bioorg Med Chem; 2010 Mar; 18(5):1806-15. PubMed ID: 20149665
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of 32Dp210 cells harboring T315I mutation by a novel derivative of emodin correlates with down-regulation of BCR-ABL and its downstream signaling pathways.
    Li J; Chen Y; Chen B; Chen C; Qiu B; Zheng Z; Zheng J; Liu T; Wang W; Hu J
    J Cancer Res Clin Oncol; 2015 Feb; 141(2):283-93. PubMed ID: 25217883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
    He B; Wang Q; Liu X; Lu Z; Han J; Pan C; Carter BZ; Liu Q; Xu N; Zhou H
    Biomed Pharmacother; 2020 Sep; 129():110390. PubMed ID: 32563150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia.
    Aranda-Tavío H; Recio C; Martín-Acosta P; Guerra-Rodríguez M; Brito-Casillas Y; Blanco R; Junco V; León J; Montero JC; Gandullo-Sánchez L; McNaughton-Smith G; Zapata JM; Pandiella A; Amesty A; Estévez-Braun A; Fernández-Pérez L; Guerra B
    Biomed Pharmacother; 2021 Dec; 144():112330. PubMed ID: 34673425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.
    Härtel N; Klag T; Hanfstein B; Mueller MC; Schenk T; Erben P; Hochhaus A; La Rosée P
    J Cancer Res Clin Oncol; 2012 Feb; 138(2):203-12. PubMed ID: 22089930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.